Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All deuremidevir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchDeuremidevirDeuremidevir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review

Xiao et al., Medicine, doi:10.1097/MD.0000000000034105, PROSPERO CRD42023391130
Jul 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Systematic review of 3 VV116 studies with 1,044 participants. Authors conclude that VV116 had minimal adverse events and was not inferior in symptomatic alleviation when compared with paxlovid. Authors note that more research into the safety and efficacy of VV116 is needed, and more elderly and critically ill patients with COVID-19 should be included.
See Ma et al. for another review covering deuremidevir for COVID-19.
Xiao et al., 7 Jul 2023, peer-reviewed, 6 authors, trial PROSPERO CRD42023391130. Contact: fellones.zero@gmail.com.
This PaperDeuremidevirAll
Abstract: Medicine ® Systematic Review and Meta-Analysis The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19 wCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdgGj2MwlZLeI= on 01/29/2024 A systematic review Ningkun Xiao, MDa,* , Xinlin Huang, MDa, Xiaotian Kang, Bachelorb, Wanli Zang, MDc, Bo Li, MDd, Sergey Kiselev, PhDa Abstract Background: Recent trials have highlighted the potential of oral antiviral VV116 in the treatment of patients with mild COVID- 19. However, no comprehensive studies have assessed the safety and efficacy of VV116. Therefore, we conducted a systematic review to assess the safety and efficacy of VV116. Methods: A comprehensive search was conducted on PubMed, Scopus, and Google Scholar websites, with a cutoff date of March 23, to identify pertinent studies. Results: The results from the 3 included studies indicated that no serious adverse events were reported in the VV116 experimental groups, which exhibited a 2.57-day faster time to viral shedding than the control group and demonstrated non-inferiority to the nirmatrelvir-ritonavir control group in alleviating major symptoms. Discussion: Collectively, available studies suggest a reliable safety and efficacy profile for VV116. However, the limited number of trials was insufficient for meta-analysis, and the included population consisted of younger individuals with mild and moderate symptoms, not encompassing the elderly who are severely affected by COVID-19. We hope that more studies will be conducted in the future to ensure that VV116 has a more reliable safety and efficacy profile in the clinical setting, especially in severe or critical patients. Abbreviations: AEs = adverse events, AUC = concentration-time curve, Cmax = the maximum measured plasma concentration, COVID-19 = corona virus disease 2019, NR = nirmatrelvir/ritonavir, PEDro = Physiotherapy Evidence Database scale, SARSCoV-2 = severe acute respiratory syndrome coronavirus 2. Keywords: COVID-19, oral antiviral drug, public health, vaccines, VV116 have high spike protein mutation rates. There is a higher probability of vaccine breakthrough rates and widespread escape from existing neutralizing antibodies,[8,9] more specifically, The BQ and XBB subvariants of SARS-CoV-2 Omicron are currently expanding rapidly, and BQ.1, BQ.1.1, XBB, and XBB.1 are the most resistant SARS-CoV-2 variations to date,[10] which poses a huge challenge to the immune protection of the majority of the population and a threat to worldwide health endeavors. Consequently, adjunct medications have become increasingly important for safeguarding global health. The U.S. Food and Drug Administration has approved 2 oral antiviral drugs for the treatment of mild to moderate COVID-19 outpatients at risk of progression to severe COVID-19: Pfizer’s PF-07321332 (nirmatrelvir/ritonavir, paxlovid)[11,12] and Merck’s
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit